[STUDY_ID_REMOVED] 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 2 of 58 CAUTION: Investigational New Drug  
Limited by Federal (or United States) Law to Investigational Use  
-----------------------------------------------  
Confidentiality Statement  
The information in this document is privileged or confidential and  may not be disclosed unless 
such disclosure is required by ap plicable laws and regulations. It is the property of ANNOVIS  
Bio, Inc. and should not be copied by or distributed to persons not involved in the study. Persons 
to whom the information is disclos ed must be informed that the information is privileged or 
confidential and may not be further disclosed by them. The se restrictions on disclosure will 
apply equally to all future information supplied to you, which is indicated as privileged or 
confidential . Any unauthorized review, use, disclosure, copying or distribution is strictly 
prohibited.    
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 3 of 58 PRINCIPAL INVESTIGATOR SIGNATURE  PAGE  
 
I, the undersigned, have reviewed this protocol and I agree to conduct this protocol in accordance 
with the ethical princip les set forth in the Declaration of Helsinki, the Guideline for Good 
Clinical Practice (ICH E6), the U.S . Code of Federal Regulations (CFR) governing the protection 
of human subjects (21CFR§50), Institutional Review Boards (21CFR§56) and the requirements 
for conducting clinical investigations (21CFR§312), and all applicable local, state and federal 
governmen t regulations and laws.  
 
SIGNATURE  
 
_______________________________________   ___________________  
Name:        Date   
 
Institution:________________________ _________________________________  
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 4 of 58 LIST OF ABBREVIATIONS  
 
5’UTR  5’ untranslated region  
αSYN  Alpha -synuclein  
Aβ Beta-amyloid  
Aβ38  Beta Amyloid 38  
Aβ40  Beta Amyloid 40  
Aβ42  Beta Amyloid 42  
AChE  Acetylcholinesterase  
AD Alzheimer’s Disease  
ADAS -Cog Alzheimer’s Disea se Assessment Scale – Cognitive  
ADL  Activities of Daily Living  
AE Adverse Event  
AIDS Acquired Immunodeficiency Syndrome  
APOE/APOE4  Apolipoprotein E /Apolipoprotein epsilon 4  
APP  Amyloid Precursor Protein  
ANOVA  Analysis of variance  
AUC  Area under the curve  
BACE  β-secretase  
BChE  Butyrylcholinesterase  
BDNF  Brain -derived neurotrophic f actor 
BID Twice a Day  
BP Blood pressure  
CDR  Clinical Dementia Rating  
CFR  Code of Federal Regulations  
CTCAE  Common Terminology Criteria for Adverse Events  
CLBP  Chronic low back pain  
Cmax  Maximum plasma and CSF concentration  
ChE Cholinesterase  
CJD Creutzfel dt-Jakob Disease  
C-SSRS  Columbia Suicide Severity Rating Scale  
CNS  Central Nervous System  
CSF Cerebrospinal Fluid  
CV Coefficients  of variation  
CVD  Cerebrovascular Dementia  
DNA  Deoxyribon ucleic Acid  
DS  Down Syndrome  
DSMB  Data Safety Monitoring Board  
DSM  Diagnostic and Statistical Manual of Mental Disorders  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 5 of 58 FCR  Fractional clearance rate  
FDA  Food and Drug Administration  
FSR Fractional Synthesis Rate  
FWA  Federal  wide Assurance  
GCP  Good Clinical Practice  
GI Gastrointestinal  
GRAS  Generally recognized as safe  
GWAS  Genome Wide Association Studies  
HEK 293  Human embryonic kidney cells  
HEENT  Head/ears/eyes/nose/throat  
hERG  Human et her-a-go-go related gene  
HIPAA  Health Insurance Portability and Accountability A ct 
HPMC  Hydroxypropyl methylcellulose   
H&Y  Hoehn and Yahr  
ICH International Conference on Harmoni zation  
IRB Institutional Review Board  
IRE Iron-responsible element  
IRP1  Iron Regulatory Protein 1  
LBD  Lewy Bodies Dementia  
LP Lumbar Puncture  
MAD  Multiple Asce nding Dose  
MCI  Mild Cognitive Impairment  
MDS -UPDRS  MDS -United Parkinson’s Disease Rating Scale  
MMSE  Mini -Mental State Examination  
MRI  Magnetic Resonance Imaging  
mRNA  Messenger Ribonucleic Acid  
NIH National Institutes of Health  
NOAEL  No observed adverse eff ect level  
NPH  Normal Pressure Hydrocephalus  
OHRP  Office for Human Research Protections  
p-tau  Phospho rylated tau 
PD Parkinson’s disease  
PHI Protected Health Information  
PI Principal Investigator  
PK Pharmacokinetic  
PSP Progressive Supranuclear Palsy  
QD Once  a Day  
QID 4 Times a Day  
QT Interval seen in electrocardiogram (E CG) test  
QTc  Interval seen in QT (E CG) test  
sAPP  Soluble Amyloid Precursor Protein  
sAPPα  Soluble Amyloid Precursor Protein alpha  
sAPPβ  Soluble Amyloid Precursor Protein  beta 
SAD  Single Ascending Dose  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 6 of 58 SAE  Serious Adverse Event  
SH-SY-5Y Human Derived Cell Line  
SILK ™ Stable Isotope Labeling and Kinetics  
SD Standard Deviation  
t1/2 Half-life 
tau Tau protein  
TID Three Times a Day  
TPN  Total Parenteral Nutrition  
WAIS -IV Weschler Adult Intelligence Scales, 4th edition  
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 7 of 58 Table of Contents  
1 PROTOCOL SYNOPSIS  ................................ ................................ ...............................  11 
2 INTRODUCTION ................................ ................................ ................................ ...........  14 
2.1 Objectives  ................................ ................................ ................................ .....................  15 
2.2 Endpoints  ................................ ................................ ................................ ......................  16 
3 PRELIMINARY STUDIES  ................................ ................................ ...........................  18 
3.1 Summary of Non -Clinical Findings  ................................ ................................ ..............  18 
3.2 Summary of Clinical Findings  ................................ ................................ ......................  18 
4 BACKGROUND AND STUDY OVERVIEW  ................................ .............................  20 
5 POTENTIAL RISKS AND BENEFITS OF INVESTIGATIONAL PRODUCT AND 
STUDY PROCEDURES  ................................ ................................ ................................ ............  23 
5.1 Risks and Benefits Associated with Posiphen or Placebo  ................................ ............  23 
5.2 Risk/Benefit Associated with Blood Collections  ................................ ..........................  23 
5.3 Risk/Benefit Associated with CSF Sampling  ................................ ...............................  23 
6 SAMPLE SIZE AND STATISTICAL PLAN  ................................ ..............................  24 
6.1 Randomization  ................................ ................................ ................................ ..............  24 
6.2 Power and Sample Size Determination ................................ ................................ .........  24 
6.3 Safety and Tolerability Analysis  ................................ ................................ ...................  27 
6.4 PK Analys is ................................ ................................ ................................ ..................  28 
6.5 Exploratory Pharmacodynamic and Efficacy Analysis  ................................ ................  28 
6.6 Criteria for the termination of the trial  ................................ ................................ ..........  28 
6.7 Interim Analysis  ................................ ................................ ................................ ............  28 
7 STUDY DRUG AND CONCOMITANT MEDICATIONS  ................................ ........  30 
7.1 Name and Description of  IP and Comparator  ................................ ...............................  30 
7.2 Dosage ................................ ................................ ................................ ...........................  30 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 8 of 58 7.3 Packaging/Dispensing/Labeling  ................................ ................................ ...................  30 
7.4 Storage  ................................ ................................ ................................ ..........................  30 
7.5 Drug Accountability ................................ ................................ ................................ ...... 30 
7.6 Compliance  ................................ ................................ ................................ ...................  32 
7.7 Breaking the Blind  ................................ ................................ ................................ ........  32 
7.8 Overdose  ................................ ................................ ................................ .......................  32 
7.9 Concomitant Medications  ................................ ................................ .............................  33 
7.9.1  Prohibi ted Concomitant Medications  ................................ .......................  33 
7.9.2  Permitted Concomitant Medications  ................................ ........................  33 
8 STUDY POPULATION  ................................ ................................ ................................ . 34 
8.1 Inclusion Criteria  ................................ ................................ ................................ ..........  35 
8.2 Exclusion Criteria  ................................ ................................ ................................ .........  36 
9 DESCRIPTION OF STUDY VISITS  ................................ ................................ ...........  38 
9.1 Screening Visit  ................................ ................................ ................................ ..............  38 
9.2 Baseline Visit  ................................ ................................ ................................ ................  38 
9.3 Day 14 Tel ephone Contact ................................ ................................ ............................  39 
9.4 Confinement Visit  ................................ ................................ ................................ .........  39 
9.4.1  Pre-Confinement Telephone Contact  ................................ ......................  39 
9.4.2  Confinement Visit  ................................ ................................ .....................  39 
9.4.3  Post-Confinement 24 -Hour Phone Follow -up ................................ ..........  42 
10 EARLY TREATMENT/STUDY DISCONTINUATION  ................................ ...........  43 
10.1  Reasons for Early Discontinuation  ................................ ................................ ...............  43 
11 STUDY -SPECIFIC INSTRUMENTS  ................................ ................................ ...........  44 
12 STUDY -SPECIFIC PROCEDURES  ................................ ................................ ............  44 
12.1  Safety Assessments  ................................ ................................ ................................ ....... 44 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 9 of 58 12.1.1  Physical and Neurological Examination  ................................ ...................  44 
12.1.2 Electrocardiogram (ECG)  ................................ ................................ .........  44 
12.1.3  Clinical Laboratory Evaluations  ................................ ................................  44 
12.2  Biofluids  ................................ ................................ ................................ ........................  45 
12.2.1  CSF for Biomarkers  ................................ ................................ .................  45 
12.2.2  APOE Genotype and other DNA Markers  ................................ ................  46 
12.2.3  Plasma for Biomarkers and Pharmacok inetics  ................................ ........  46 
12.2.4  Blood Samples for Exosomes  ................................ ................................ .. 47 
13 PERSONNEL REQUIREMENTS  ................................ ................................ ................  47 
14 ADVERSE EVENTS (AES)  ................................ ................................ ...........................  47 
14.1  Definition  ................................ ................................ ................................ ......................  47 
14.2  Following Up on AEs  ................................ ................................ ................................ ... 48 
15 SERIOUS ADVERSE EVENTS (SAE)  ................................ ................................ ........  48 
15.1  Definition  ................................ ................................ ................................ ......................  48 
15.2  Reporting SAEs  ................................ ................................ ................................ ............  48 
16 DATA AND SAFETY MONITORING BOARD (DSMB)  ................................ .........  49 
17 RECORDING AND COLLECTION OF DATA  ................................ .........................  49 
17.1  Electronic Case Report Form (eCRF)  ................................ ................................ ...........  49 
17.2  Study Files and Source Documents  ................................ ................................ ..............  50 
18 ETHICS AND REGULATORY CONSIDERATIONS  ................................ ...............  50 
18.1  Good Clinical Practice  ................................ ................................ ................................ .. 50 
18.2  Institutional Review Board (IRB)  ................................ ................................ .................  51 
18.3  Informed Consent and Health Insurance and P ortability and Accountability Act 
(HIPAA) Compliance  ................................ ................................ ................................ ...............  51 
19 STUDY MONITORING  ................................ ................................ ................................  52 
20 AUDIT  ................................ ................................ ................................ ..............................  52 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 10 of 58 21 RECORD RETENTION  ................................ ................................ ................................  52 
22 LITERATURE CITED  ................................ ................................ ................................ .. 54 
23 APPENDIX 1: SCHEDULE OF EVENTS  ................................ ................................ ... 56 
24 APPENDIX 2: SEVERITY EVALUATION OF CHOLINERGIC ADVERSE 
EVENTS (ADVERSE EVENTS OF SPECIAL INTEREST)  ................................ .................  58 
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 11 of 58 1 PROTOCOL SYNOPSIS  
PROTOCOL TITLE  A Multicenter, Randomized, Double -Blind, Placebo -Controlled , Dose -
Finding Study to Evaluate the Safety, Tolerability, P harmacokinetic  and 
Pharmacodynamic  Effects of Posiphen® in Subjects with  Early 
Alzheimer’s Disease (AD) or  Early  Parkinson’s Disease  (PD)  
STUDY DESIGN  This study will be co nducted in two parts.   
Part 1  will evaluate the safety , tolerability,  and pharmacokinetics of  
Posiphen in 14 Early AD and 14 Early PD patients at the  following dose:  
• 80 mg QD  
Each group will include 14 Early AD patients , randomly assigned , 10 to 
Posiphen  and 4 to placebo and 14 Early PD patients randomly assigned, 
10 to Posiphen and 4 to placebo . 
Part 1 of the st udy will also include exploratory measures of 
pharmacodynamics and efficacy of Posiphen with target engagement, 
pathway engagement and functional/ cognitive measures, including the 
degree of memory loss and cognitive function in AD patients as well as 
the d egree of motor impairment and non -motor symptoms and quality of 
life in PD patients.  
Subjects who drop out during the initial 3 -week at -home treat ment period 
will be discontinued and replaced by new subjects. If 4 subjects are 
discontinued due to adverse e vents, no additional subjects will be 
recruited until a safety review has been conducted.  
After Part 1 has been completed study data will be locke d to allow a full 
analysis of biomarker data to sensitize analysis plans in Part 2.  
Part 2  will evaluat e the safety , tolerability,  and pharmacokinetics of 
Posiphen in 40 patients with early PD, randomly assigned to the 
following dose levels , 10 patients per dose level :  
• 5 mg  QD 
• 10 mg  QD 
• 20 mg  QD 
• 40 mg QD  
Part 2 of the study will also include exploratory measures of 
pharmacodynamics and  efficacy of Posiphen in Early PD patients with 
target engagement, pathway engagement and functional/cognitive 
measures, i ncluding the degree of motor impairment as well as o ther non -
motor symptoms and quality of life  in PD patients . 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 12 of 58 Subjects who drop out during the initial 3 -week at -home treatment period 
will be discontinued and replaced by new subjects. If 4 subjects are 
discontinued due to adverse events, no additional subj ects will be 
recruited until a safety review has been conducted . 
DURATION OF STUDY 
PARTICIPATION  Each subject will have up to a 42 -day screeni ng period,  a baseline visit 
including a lumbar puncture (LP),  followed by 25±2 days of treatment  at 
home , followed by an in clinic visit  that includes treatment and a 6-hour 
LP procedure . 
SUMMARY OF 
INVESTIGATIONAL 
PRODUCT  Part 1: Posiphen /placebo 80 mg QD, taken orally  for 25±2 days by Early 
AD and PD patients . 
 
Part 2: Posiphen at 5, 10, 20, or 40 mg QD, taken orally for 25±2 days by 
Early PD patients .  
SUMMARY OF KEY 
ELIGIBILITY CRITERIA :  
FOR AD • Diagnosis of early AD  
• Age 45 or older  
• MMSE 18-28 
• Clinical Dementia R ating (CDR) of 0.5 or 1.0  
SUMMARY OF KEY 
ELIGIBILITY CRITERIA :  
FOR PD • Diagnosis of early PD  
• Age 45  or older  
• MMSE 18-30 
• Hoehn & Yahr ≤ 4 
PRIMARY OUTCOME 
MEASURE S Aim 1.  Safety and Tolerability  
Aim 2.  PK of Posiphen in Plasma  
EXPLORATORY  
MEASURES  TARGET ENGAGEMENT  
Levels of neurotoxic proteins in blood, plasma and CSF : 
• aSYN and Aβ monomers and dimers , and infective oligomers   
• Aβ38, Aβ40, Aβ42  
• soluble Amyloid Precursor Protein s:  sAPP α and sAPPβ  
• T-Tau and P-Tau proteins  
PATHWAY ENGAGEMENT  
Levels of proteins involved in the toxic cascade leading to nerve cell 
death in blood, plasma and CSF  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 13 of 58 • Neurotransmi tters 
• Neurotrophic factors  
• Inflammatory factors  
• Synaptic factors  
• Control proteins that  should not change  
FUNCTIONAL/COGNITIVE  MEASURES  
PD: MMSE, WAIS -IV, MDS -UPDRS  
AD: MMSE, WAIS -IV, ADAS -Cog 14, CDR   
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 14 of 58 2 INTRODUCTION  
Currently,  there  is no treatment  availa ble to stop or reverse  the progression  of Alzheimer’s  
(AD)  and Parkinson’s  disease  (PD) . Neurodegenerative  diseases  such as AD and PD share  
many  common  characteristics,  including  the central  role of neurotoxic  aggregating  proteins  
in their  pathogenesis.  Amyloid  β (Aβ)  and tau aggregates  (senile  plaques  and neurofibrillary  
tangles , respectively)  have  been  traditionally  associated  with AD, while  α-synuclein  (αSYN)  
aggregates  (Lewy  bodies)  have  been  associated  with PD.  However,  it is becoming  
increasingly  clear that all these  proteins  are involved  in both diseases  and that aggregati on 
of one can lead to accumulation  of another.  Furthermore,  in several  studies  of brains  from  
older  patients,  a high percentage  of all AD brains  present  mixed  pathologies,  such  as Lewy 
body  disease.  Several  clinical  trials  targeting  just one (often  Aβ) of the neurotoxic  
aggregating  proteins  have  failed.  Finally,  other  fragments  of Amyloid  β Precursor  Protein  
(APP)  have  been  implicated  in AD pathology.  Collectively,  these  facts  point  to the need  for 
development  of combination  therapies  that target  multiple  neurotoxic  aggregating  proteins  
simultaneously,  if we are to have  a good  chance  of at least  halting  disease  progression.  
Posiphen  has a unique  mechanism  of action,  in that it inhibit s the translation  and, therefore,  
reduces  the levels  of several  neurotoxic  aggregating  proteins  both in vitro  and in vivo, including  
α-Synuclein  (αSYN),  Amyloid  Precursor  Protein  (APP),  its fragments,  and tau. All three  proteins  
have  been  implicated  in the pathogenesis  of PD.  Furthermore,  at older  ages,  there  is a high 
incidence  of patients  with mixed  pathologies,  such as PD dementia.   Therefore,  it is reasonable  to 
hypothesize  that inhibiting  expression  of all three  proteins  should  lead to a better  efficacy  
outcome  in PD patients  than inhibiting  just one. 
Posiphen’s  safety  has been  established  in three  Phase I clinical  studies  by Macc ecchini  et al. 
Importantly,  Posiphen  normalized  levels  of αSYN,  APP,  and tau in the cerebrospinal  fluid  (CSF)  
of mildly  cognitively  impaired  (MCI)  patients  at a dose of 4x60  mg/day  (Protocol  QR12001) . 
Preclinical  data proves  Posiphen’s  efficacy  in restorin g colonic  motility  in a human  SNCAA53T tg 
mouse  model  of early  PD, in restorin g memory  and learning  in an APP/PS1  transgenic  (tg) 
mouse  model  of AD, restoring  axonal  transport  in DS trisomic  mice,  preserving  memory  and 
learning  in traumatic  brain  injury  rats and preserving  the retina  in acute  glaucoma.  
αSYN,  APP,  and tau contribute  to the progression  of AD and PD in similar  ways:  they impair  
axonal  transport  and lower  neurotransmitter  and neurotrophic  factor  release,  they cause  
inflammation,  they form  aggregates,  and, finally,  they lead to nerve  cell death. In our in vitro  and 
in vivo preclinical  studies,  Posiphen  has normalized  all those  actions . 
We have conducted a proof -of-concept study in mildly cognitive impaired patients at 4x60 
mg/day  (Protocol QR12001)  and found that Posiphen lowers levels of neur otoxic proteins and of 
inflamm atory markers.  Presently, we are testing Posiphen in the DISCOVER study at 1x60, 
2x60 and 3x60 mg/day for up to 25 days to see if it changes the synthesis and degradation 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 15 of 58 kinetics of Aβ in a stable isotope labelling kinetic ( SILK) study.  The DISCOVER stu dy is on -
going through the ADCS and is planned for 24 patients to be enrolled; currently, approximately 
half of the study has been enrolled, and there have been no severe AE s or SAE s attributed to 
Posiphen reported.  
From our animal data, we found that P osiphen works in more than Alzheimer animals, because it 
inhibits more than one neurotoxic protein.  We found that in transgenic AD and PD animals it 
lowers levels of neurotoxic proteins and restores the affected functi on.  Therefore, we want to 
test Posip hen in a comparison study of AD and PD patients and measure not just target 
engagement, but also pathway engagement.  
From our animal data, we also found that the doses used to show an effect on neurotoxic proteins 
are very high and that we can see an effe ct of Posiphen at much lower doses. Therefore, we are 
testing Posiphen in a randomized dose de -escalation study to see what the lowest effective dose 
is in humans.  
In this study, we want to find out if the animal Posiph en data can be replicated in humans  and 
show target and pathway engagement in CSF.  Target engagement means that Posiphen would 
lower and normalize the levels of neurotoxic proteins in CSF .  Pathway engagement means that 
Posiphen would increase levels of neurotransmitters, neurotrophic factor s, and lower levels of  
inflammatory and neurodegeneration markers in both AD and PD patients .  By examining all 
these factors in early AD and PD patients, we will specify the biomarkers that change with 
Posiphen treatme nt, which will be used in late r phase  studies.  Additionally, we will assess 
function and cognition, so we can make sure that Posiphen has no deleterious effect and 
potentially identify any improvement.  Collectively, these endpoints will help assess the e fficacy 
of Posiphen and drive it to l ate phase clinical studies.  
2.1 Objective s 
Study objectives include assessing safety, tolerability , and pharmacokinetics of Posiphen as well 
as exploring pharmacodynamics and efficacy in Early AD and Early PD patients with target 
engagement, pathway engagement  and functional/cognitive measures being the focus of the 
exploratory analyses.   This study wil l be conducted in two parts  as follows .   
Part 1   
Primary objectives are to assess the safety , tolerability, and pharmacokinetics of Posiphen in 14 
Early AD and 14 Early PD patients at a dose of 80 mg QD  for 25±2 days . 
Each group will include 14 Early AD patients , randomly assigned, 10 to Posiphen and 4 to 
placebo and 14 Early PD patients  randomly assigned, 10 to Pos iphen and 4 to placebo.  
Exploratory objectives w ill include investigating the pharmacodynamics and efficacy of 
Posiphen as well as the relationship between them.  Efficacy assessments will focus on the 
following:  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 16 of 58 • degree of memory loss and cognitive functi on in AD patients  
• degree of motor impairment and  non-motor symptoms and quality of life in PD patients.  
Part 2   
Primary objectives are to assess  the safety tolerability, and pharmacokinetics of Posiphen in 40 
patients with early PD, 10 patients randomly a ssigned to each of the following dose levels , given 
for 25±2 days :  
• 5 mg QD  
• 10 mg QD  
• 20 mg QD  
• 40 mg QD  
Exploratory objectives will include investigating the pharmacodynamics and  efficacy of 
Posiphen as well as the relationship between them.  Efficacy assessments will focus on the 
degree of motor impairm ent in PD as well as other non -motor symptoms and quality of life.  
2.2 Endpoint s 
 
SAFETY AND TOLERABILITY  
• adverse events  
• physical examinations  
• vital signs   
• 12-lead ECGs  
• clinical laboratory values  
 
PHARMACOKINETICS  
PK parameters will minimally be determined, a s data permit: Area under the curve (AUC), 
Cmax, Tmax, t½, and CL . 
 
Additionally, the following Exploratory Objectives will be evaluated:  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 17 of 58  
TARGET ENGAGEMENT  
Levels of neurotoxic proteins in blood, plasma and CSF  
• aSYN and A β monomers and dimers , and infecti ve oligomers  
• Aβ38,40,42  
• soluble Amyloid Precursor Protein s:  sAPPα and sAPPβ  
• T-tau and P-tau protein   
 
PATHWAY ENGAGEMENT  
Levels of proteins involved in the toxic cascade leading to nerve cell death in blood, plasma and CSF  
• neurotransmitters  
• neurotrophic f actors  
• Inflammatory factors  
• Synaptic factors  
• Control proteins  that should not change  
 
FUNCTIONAL /COGNITIVE MEASURES  
PD: MMSE,  WAIS -IV, MDS -UPDRS  
AD: MMSE , WAIS -IV, ADAS -Cog 14 , CDR  
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 18 of 58 3 PRELIMINARY STUDIES  
 
The f ollowing is a brief summary of the available  information on Posiphen. D etailed information  
can be found in the current Posiphen Clinical Investigational Brochure . 
3.1 Summary of Non -Clinical Findings  
In wild type mice, Posiphen lowered brain APP and A β levels by up to 60% ( Lahiri 2007 , 
Cullen  2006 ). In APP transgenic AD mice, Posiphen led to a decrease in APP levels, improved 
neuronal stem cell survival and increased le vels of brain-derived neurotrophic factor  (BDNF ) 
(Marutle 2007 ; Kadir 2008 , Lilja 20 13). Chronic administration of Posiphen to APP transgenic 
mice totally prevented decline in memory and learning as well as in long -term potentiation at 
brain and plasma con centrations that are 10 times lower than originally published. These plasma 
levels a re attainable with low oral dosing in humans ( Teich 2018 ). In alpha -synuclein  (αSYN) 
transgenic PD mice, Posiphen restored gut motility to normal and lowered aSYN  in the brain and 
gut of the tg PD mice. Again,  the efficacious levels were 10 times lower than originally 
published (Kuo 2019 ). In DS trisomic mice Posiphen fully restored axonal transport in vitro  and 
in vivo  (Mobley Lab, UCSD, 2019; manuscript submitted  for publication).  In summary, Posiphen 
is a translational inhibitor of APP and aSYN and fully restores function at doses that are very 
low and very safe.  
Posiphen was not m utagenic or clastogenic as assessed by in vitro  assays.  
The cardiac electrophysiol ogical properties of Posiphen tartrate were negative in vitro  using 
human ether -a-go-go related gene  (hERG ) transfected human embryonic kidney cells (HEK 
293). Posiphen did not adversely af fect the interval seen in an electrocardiogram (E CG) test ( QT 
(or QTc) ) interval.   
Toxicity studies in dogs showed brain toxicity (ataxia and tremors/twitching) and gastrointestinal 
(GI) toxicity at 30 mg/kg/day, which was dose -dependent an d reversible. The no observed 
adverse effect level  (NOAEL ) was 20 mg/kg/day in  dogs. Posiphen readily crosses the blood -
brain barrier. The signs/symptoms noted at high doses of Posiphen may be related to cholinergic 
manifestations. In in vitro assays, Posi phen showed minimal inhibition of AChE or BChE 
(Butyrylcholinesterase) activit y, however, a metabolic product of Posiphen, N1-norposiphen 
demonstrated acetyl cholinesterase inhibitory activity ( Yu 2013 ). There were no effects on the 
reproductive organs ass ociated with 4 -week exposure to Posiphen in male or female rats or dogs.  
3.2 Summ ary of Clinical Findings  
Three Phase  1 studies have been conducted  with Posiphen  (IB 2019). The first was a single 
ascending dose ( SAD ) study in healthy volunteers; the second w as a multiple ascending dose 
(MAD ) study in healthy volunteers , and the third one was a pharmacokinetic 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 19 of 58 (PK)/pharmacodynamic  study of CSF obtained from mild cognitively impaired participant s 
(Protocol QR12001) .  
In the MAD  trial, Posiphen was administered orally in doses of 20, 40, and 60 mg 4 times a day 
(QID). The first two treatments were administered for 7 days, and the third, for 10 days. Single 
doses were given on the first and last day to determine the pharmacokinetics of the drug. In 
general , the dr ug was well tolerated, resulting in no serious or severe adverse events and only 
one premature disco ntinuation, a subject in the 60  mg group discharged because of nausea, 
vomiting, dizziness and “feeling warm .” The incidence of adverse events, all e ither m ild or 
moderate severity , also occurred with similar frequency in the placebo group. The most common 
AEs were dizziness, headache, and nausea/vomiting.  
Posiphen was absorbed rapidly after oral administration, achieving maximum plasma and CSF 
concen tration  (Cmax) within 1.2 - 1.5 hours. For the 40 and 60 mg doses, with fully defined 
plasma profiles, the mean terminal t ½’s were 3.80 ± 0.88 and 5.23 ± 1.24 hours, respectively after 
a single dose and 3.53 ± 1.03 and 4.104  ± 0.91 hours, respectively, a fter re peat dosing. The half-
life ( t½) of the plasma concentrations at the lower doses could not be calculated accurately. The 
Cmax increased disproportionally with dose (24, 144, and 2310 ng.h/mL after a single dose of 20, 
40, and 60 mg, respectively and 110, 13 4, and 2101 ng.h/mL after multiple doses of 20, 40, and 
60 mg, respectively).  
In the proof of mechanism of action study  (Protocol QR12001) , the PK of Posiphen was 
measured after 10 days of administration (4x60 mg) over 6 hours in CSF and plasma of the AD 
participant s. The pharmacodynamics  of a number of biomarkers was compared for 6 hours 
before the first dose at day 0 and after the last dose  at day 11 of Posiphen administration.  We 
found that the plasma concentrations of Posiphen overlapped with the plasma  concentrations 
found in the MAD study. In this study, the N1 metabolite reach ed about 10 to 15%, while the 
level of the N8 metabolite reac hed about 20 to 25% of the Posiphen levels measured in plasma.  
Because a substantial proportion of the adverse event s observed in AD patients treated with 
cholinesterase inhibitors appear to reflect the cholinomimetic properties of molecules in this 
class , Posiphen’s highest tolerated dose is determined by the levels of the N 1-norposiphen in 
blood and brain.  
While the t1/2 of Posiphen in plasma was 5 hours as seen in the SAD and MAD studies, the t1/2 in 
CSF/brain was longer than 12 hours. Concentrations of Posiphen in the brain, extrapolated from 
blood and CSF, were 8 times higher than in plasma. 10 days of treatment wit h Posiphen 
normalized CSF levels of sAP P, tau, αSYN and a series of inflammatory m arkers. The 
concentration and persistence of Posiphen in the brain suggest that much lower doses of drug 
administered once daily could achieve the desired pharmacological effect.  
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 20 of 58 4 BACKGROUND AND STUDY OVERVIEW  
4.1 Background  
A major pathological hallmark of AD is the appearance of plaques and tangles in the brain and of 
PD the appearance in the gut and in the brain of aSYN aggregates that form Lewy bodies . In 
both diseases t hese aggregates  are thought to occur one o r two decades prior to overt symptom 
development . Recent research has shown that soluble forms of phospho rylated tau (p -tau) and 
Aβ may also contribute to neuronal loss and that PD as well as AD carry a high load of 
inflammation a nd microglia activating factors that contribute to neurodegeneration.  
For small molecules that target biomarker levels, studies using CSF and plasma sampli ng in 
humans can provide data to demonstrate that a drug crosses the blood -brain barrier and engages 
the relevant target, and to describe the relationship between blood levels and CNS effects. 
Repeated sampling through a lumbar CSF catheter for 6 hours  can mirror image, what happens in 
the brain as to the levels of aSYN monomers and dimers, Aβ monomers an d dimers as well as 
other biomarkers and help guide the development of drugs targeting neurotoxic aggregating 
proteins .  
Posiphen is the (+) enantiomer of p henserine, an AChE  inhibitor which had been tested in 
several AD studies without significant evidence of efficacy . While phenserine inhibits AChE, 
Posiphen has no AChE activity itself and develops some activity in vivo with the metabolism to 
N1-bisnorposip hen. In vivo phens erine has about 200 times more AChEI activity  than 
Posiphen’s metabolite N1 -bisnorposiphen. Posiphen absorption is affected by food; however, at 
steady state there is no effect on the PK analyses results.  
Posiphen has been found to signif icantly reduce soluble APP and A β as well as tau, p -tau and 
αSYN  in the rodent brain and  in human CSF. In preliminary studies in animals and humans , 
inhibition of APP, A β, tau, p -tau and αSYN  occurs at levels 6 to 10 times lower than the levels 
causing cho linomimetic effect s. 
Posiphen act s at the 5’UTR of the  aSYN and  APP mRNA and lowers their protein expression 
levels in animal models ; it also  decreased aSYN and sAPP levels in human CSF. Our data 
suggests that these effects are achieved via the same mechan ism: the 5’UTR s of these mRNAs 
form a complex with iron regulatory protein 1 and Posiphen stabilizes the complex, thereby  
inhibiting the translation  of these mRNAs . 
As Posiphen  inhibit s the synthesis of aSYN and APP, as well as other neurotoxic aggregating  
proteins , it might have a broader spectrum of activity than PD and AD. By  protect ing neurons  
from dying it has a disease -modifying effect in PD, AD as well as other neurodegenerative 
disorders.  
4.2 Study  Overview  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 21 of 58 Study population:  The study will be condu cted in patients  with early  AD or early  PD. 
Dose selection : In Part 1 Posiphen will be tested at 80 mg QD  and in Part 2, Posiphen will be 
tested at 5, 10, 20, 40 mg QD , for 25±2 days.   
Whereas, the plasma t½ of Posiphen has been determined to be 5 h ours, the CNS t½ has been 
measured  to be over 12 hours, allowing that once daily dosing is feasible.   Previous  studies 
indicated that likely cholinergic adverse events are mostly driven by Cmax  and occur at 160mg 
QD.  Since our maximum dose is 80 mg QD, we  do not expect any cholinomimetic effects.  
Study Design:  Part 1  is a study  with 14 Early AD and 14 Early PD patients  who are randomized 
to 80 mg of Posiphen or placebo.  They will undergo a Screening Visit, and if they provide 
informed consent and are con sidered eligible per the inclusion and exclusion criteria, will 
proceed to participate in the treatment period.  Period 1  consists of first-time dosing in clinic 
with administ ration of 80 mg of Posiphen  or Placebo .  Period 2  consists of an at hom e dosing 
period of 25±2 days, with  daily  administration of  80 mg of Posiphen  or Placebo .  Period 3 will 
be comprised of a stay at the clinical research unit where the subject will undergo study 
procedures that include safety assessments (AE and concomita nt medication monitoring, 12 -lead 
ECGs, clinical laboratory testing, vital signs assessments, and physical examinations), the last 
dose of Posiphen  or Placebo , and 6 hours of PK blood and CSF sampling .  At the end of 
blood/ CSF sampling, the subjects will need to stay for a minimum of 1 hour of observation but 
may stay if necessary for observation until the following  day (e.g., if the  subject has blood/CSF 
sampling on Day 25, he/she may stay for observation until Day 26 ).   After all  end-of-study 
procedures are complete , the subject will be discharged to home.   A 24 -hour follow -up call will 
occur to assess the participants current condition and if there are any additional adverse events to 
report.   
After completi on of  Part 1  of the study , the plasma and CSF samples will be analyzed for the 
biomarkers  to determine if changes are needed to the biomarkers to be measured in  Part 2 .  Since 
the conduct of the study in Part 2 will be identical to the conduct of the study in Part 1, 
recruitment will continue uninterrupted.  The only potential change between Part 1 and Part 2 are 
the biomarkers to be measured . 
Part 2  is a study wit h 40 Early PD patients , 10 patients each  who are randomized to one of 4 
treatment conditions  of Posiphen  (5 mg, 10 mg, 20 mg, or 40 mg) . They will undergo a 
Screening Visit, and if they provide informed consent and are considered eligible per the  
inclusion  and exclusion criteria, will proceed to participate in the treatment period .  Period 1  
consists of first-time dosing in clinic with administration of 5, 10, 20 , or 40mg  of Posiphen .  
Period 2  consists of an at hom e dosing period of 25±2 days, with  daily  administration of  5, 10, 
20, or 40mg  of Posiphen .  Period 3 will be comprised of a stay at the clinical research unit where 
the subject will undergo study procedures that includ e safety assessments (AE and concomitant 
medication monitoring, 12 -lead ECGs, clinical laboratory testing, vital signs assessments, and 
physical examinations), the last dose of Posiphen  or Placebo , and 6 hours of PK blood and CSF 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 22 of 58 sampling .  At the end of blood/ CSF sampling, the subject   will need to stay for a minimum of 1 
hour of observation but may stay if necessary  for observation until the following  day (e.g., if the 
subject has blood/CSF sampling on Day 25, he/she may stay for observation until Day 26).  After 
all end-of-study procedures are complete , the subject will be discharged to home.   A 24 -hour 
follow -up call will occur to assess the par ticipant ’s current condition and if there are any 
additional adverse eve nts to report.   
For both parts, s ubjects who drop out  during the initial 3 -week at home treatment period will be 
discontinued and replaced by new subjects.  If 4 subjects are discontinued due to adverse events 
a safety review will be  conducted.  
Outcome measures  to assess pharmacodynamics : Trans lational  inhibition of the aSYN mRNA 
will result in decreased production of aSYN , which may be reflected by decreased secretion of 
the aSYN monomers  and oligomers into the spinal fluid . Similarly, translational inhibition of the 
APP mRNA will result in decreased produc tion of APP and its fragments, which may be 
reflected by decreased secretion of the Aβ monomers and oligomers into the spinal fluid. We 
also will measure secr eted sAPP α and sAPP β and levels of tau and p -tau in CSF. sAPP  reflects 
processing of APP by α-secretase to produce sAPP α and β-secretase (BACE) to produce sAPP β. 
Tau levels are being measured since  we found that  tau translation may be under the regulation of 
a similar iron-responsible element (IRE) that may also be affected by P osiphen treatment . In fact, 
we have measured in human CSF and in mouse brain that tau and p -tau levels are lowered by 
Posiphen treatment.  
Safety outcome measures: Reports of adverse events ( AEs) and serious adverse events ( SAE s) 
during exposure to Posiphen will be collected  to ev aluate if there are any significant clinical 
safety issu es for  the study population.  All SAEs occurring up to 30 days after la st study drug 
administration that are considered drug -related must also be rep orted.  Extensive clinical and 
laboratory safety data  already exist for Posiphen ; therefore , this approach will be sufficient in the 
proposed study.  
Clinical , functional  and cognitive assessment measures:  Although clinical benefit is unlikely 
due to the sho rt duration of this study , AD and PD specific tests will be performed . It is predicted 
that cognition and function will remain stable over the course of drug exposure; however, this 
will be assessed formally in the clinic.  For both populations, the MMSE (Folstein  1975 ) will be 
administered as a global meas ure of cognition and  the Coding subtest from the Weschler Adult 
Intelligence Scales, 4th edition  (WAIS -IV) will serve as a sensitive measure of CNS dysfunction .  
The subjec ts with AD will also be administered the ADAS -Cog 14 (Schafer 2012 ).  The subjects 
with PD will be administered the Hoehn & Yahr (1967)  for determination of inclusion into the 
study .  Functional impairment will be evaluated using the Clinical Dementia Rating  (CDR)  scale  
(Berg1988 ) for AD and the MDS -UPDRS  (Goetz 2008 ) for those with PD.    
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 23 of 58 5 POTENTIAL RISKS AND BENEFITS OF INVESTIGATIONAL PRODUCT 
AND STUDY PROCEDURES  
5.1 Risk s and Benefit s Associated with Posiphen or Placebo  
There are no benefits to the subjects other than receiving medical and selective functional and 
cognitive evaluations.  
The clinical investigator must  advise all potential subjects of the possibility of unexpected side 
effects and carefully evaluate each person exposed to Investigational Product for possible AEs.  
Side effects to the Placebo are not uncommon but are obv iously not due to a pharmacological 
agent  as an industry standard placebo (non -lactose compound ) will be provided.  The placebo  
used for the study consists of  microcrystalline cellulose  which is generally recognized as safe 
(GRAS), with no known side effect s anticipated.  
In clinical studies to  date, Posiphen has been well tolerated with single doses o f 80 mg or  less 
and QID doses of 60 mg  up to 25 days . A higher  single dose of 160 mg was associated with an 
increased incidence of nausea and vomiting , potentia lly cholinergic based side effects , which 
resulted in the decision not to test higher single doses . Aside from nausea and vomiting, which 
are well -known responses to treatment  with ChE inhibitors, the only consistent pattern of AEs 
entailed dizziness/faint ing, headache, and reduction in tota l serum protein. These effects w ere 
seen to varying degrees at all doses of Posiphen and also in the Placebo group. There was a 
tendency, but no definitive pattern of increased incidence of AEs with increasing dose of 
Posiphen. There have been no  SAEs in p rior clinical studies with Posiphen.  
Definitive reproductive and developmental toxicity studies have not been conducted with 
Posiphen.  As a result, w omen of childbearing potential will be excluded from participati ng in 
this study.  
5.2 Risk/Benefit Associated with Blood Collections  
Phlebotomy is associated with mild to moderate discomfort due to piercing of the skin. This can 
be minimized with the use of a well -trained phlebotomist/nurse. Sometimes the blood draw site 
may beco me discolored with a “br uised” appearance that is transient and not painful. Rarely, the 
blood draw site may become infected and require antibiotic treatment.  
5.3 Risk/Benefit Associated with  CSF Sampling  
The most frequent adverse event associated with these s tudies was post -lumbar p uncture 
headache . This was successfully managed by blood patching if a participant is unresponsive to 
orally administered fluids and/or caffeine.   
Other potential risks include meningitis, pain or tingling sensation in the lower ext remities, 
temporary eye weakness or double vision, infection or bleeding at the site of catheter insertion, 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 24 of 58 pain at the site of insertion,  backache, epidural or subdural bleeding, infection, paralysis and 
potentia l injury to the nerve root.  
6 SAMPLE SIZE AN D STATISTICAL PLAN  
For P art 1:  A sample size of up to 2x14  subjects ( 10 randomized to Posiphen and 4 to Placebo 
for AD and PD respectively) is planned.  
For Part 2:  A sample size of up to 40 Early PD patients  is planned to be randomized to 
Posiphen , 10 p atients each dosed  at 5 mg, 10 mg, 20 mg, or 40 mg .   
Definitions of the analys is populations  and a detailed description of the analysis rules will be 
presented in a separate  Statistical Analysis Plan (SAP).  
6.1 Randomization  
Subjects who have signed an inf ormed consent and meet screening eligibility requirements will 
be randomly assigned  to the active and placebo treatment groups (10 randomized to Posiphen 
and 4 to Placebo for AD and PD , respectively)  in Part 1.  In Par t 2, 40 Early PD patient s will be 
randomly assigned , 10 patients each  to one of the 4 different dose levels of Posiphen (5, 10, 20 
or 40mg) .  
6.2 Power and Sample Size Determinatio n 
This is an exploratory study  to assess safety, tolerability and pharmacokinetics for Early AD and 
Early PD patients  in ad dition to investigating pharmacodynamics and efficacy focusing on target 
engagement, pathway engagement and functional/cognitive measures.  10 patients per dose 
group provides enough data to characterize the PK of Posiphen as well as adequately suppo rting 
potential dose proportionality analyses.   
 
Due to the sample size computation below , we will state that sAPP α, sAPPβ and aSYN  were 
given  specific consideration in deciding the need to have 10 Posiphen patients in each treatment 
group given their specific importance in the emergence and progression of AD and PD. The 
statistical background and rational for having 10 Posiphen pat ients in ea ch treatment group to 
have a meaningful interpretation of sAPP α, sAPPβ and aSYN data are outlined below.  
The statistical evaluation of our previous study in MCI patients with soluble APPα and β levels 
measured in spinal fluid before and after Po siphen administration (Protocol QR12001) can be 
used to power this study (Maccecchini 2012 ). All assay data collected were analyzed using a 
repeated measure  mixed model analysis of variance. The model included Day (Day 11/Day0) as 
a fixed effect, Time (9 t ime points per person between 0 and 6 hours) as a repeat measure effect 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 25 of 58 and Patient (18 samples per person total) as a random effect. Data are presented as means ±SEs. 
The statistical evaluations were undertaken by Data Magik (Salisbury, UK).  
 
 
Analysis  of sAPPα  and β using  type,  day and id as variables  shows:  
The results  of the 10 days at 8 hours  on sAPPα and β is SD = 0.1695.   
Assuming type one error, α=0.05 and type two error, β=0.2, or a power of 0.8, the calculated 
sample range of delta eff ect sizes was 0.3 to 2 SD.  

Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 26 of 58  
  

Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 27 of 58 sAPPα  
Using the above data,  we can calculate that a power analysis of APPα shows the requirement of 
9 people to see a 36% change in sAPPα levels at a statistical significance level of >0.05
 
sAPPβ  
Using the above data,  we can  calculate that a power analysis of A PPβ shows the requirement of 9 
people to see a 24% change in sAPPβ levels at a statistical significance level of >0.05 . We are 
expecting changes in sAPPα and β levels to be between 20 and  50% and  for the higher doses  an 
n<5 would be  adequate to detect thos e changes.  
aSYN  
However, we do not expect the changes in alpha -synuclein and in neurotransmitters to be that 
pronounced. Therefore, we chose an n=10. If dropouts are to occur,  they will be replaced to 
allow the full sa mple size of 5 x 10 participants to be achieved.  
6.3 Safety and Tolerability Analysis  
Safety and tolerability will be assessed with physical examinations, vital signs, clinical 
laboratory values, 12-lead ECG, use of c oncomitan t medications, and AE reports. The 
frequencies of adverse events, serious adverse events and laboratory abnormalities between the 
participants across the treatment  groups  will be compared . The severity of cholinergic adverse 
events will be careful ly evaluated  taking the criteria in Appendi x 2 into consideration (modified 
from the latest version of the Common Terminology Criteria for Adverse Events (CTCAE ) ) as 
there  is potential for an interaction  between Posiphen and Donepezil throu gh the inhibit ion of 
AChE, thereby resultin g in increas ed cholinergic activity.   

Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 28 of 58 Subjects who dropout during the initial 3 -week at -home treatment period will be discontinued 
and replaced by new subjects. If 4 subjects are discontinued due to adverse events  a safety 
review will be  conducted.  
6.4 PK An alysis  
Plasma concentration -time data will be analyzed  by non-compartmental metho ds using SAS 
version 9.4 or greater.   Calculations  will be based on the actual sampling  times  recorded during  
the study.  Since the study is blinded , all subjects ’ plasma will be included in the  PK analysis .  
From the plasma  concentration -time data, the  following  PK parameters will minimally be 
determined, as data  permit: Area under the curve ( AUC ), Cmax, Tmax, t½, and CL .  Dose -
proportion ality may be assessed on Cmax  and AUC  as appropriate. Serial pre -dose trough  
concentrations C max will be assessed for  the attainment of steady state . 
Plasm a concentration -time data for Posiphen will be listed and summarized descriptively  
(number of  subjects  (N), mean, median, standard deviation (SD), minimum (min), and 
maximum (max))  and graphically  presented.   PK parameters will be listed and summarized 
descr iptively  (N, mean,  median, SD, min, max, and 95% CI) by each dose regimen.   In addition, 
geometric means and between -subject  coefficients of variation (CV)  will be  calculated . 
6.5 Exploratory  Pharmacodynamic and Efficacy Analysis  
Pharmacodynamics and e fficacy analyses will focus on exploratory endpoints outlining target 
engagement, pathway engagement and functional/cognitive measures being the reference stones 
of the exploratory analyses both for Part 1 and Part 2.  
Analysis will include descriptive summ ary tables, listings and figures for Part 1 and Part 2 as 
well as combined analyses of dose/treatment groups from Part 1 and Part 2. Statistical 
comparisons will be descriptively performed for PD  and efficacy parameters as well as the 
relationship s between  them  using mixed models.  
6.6 Criteria for the termination of the trial  
The trial may be terminated by the Project Directors and/or the Sponsor  based on issues of 
safety, feasibility, and Data Safet y Monitoring Board ( DSMB ) recommendations.  
6.7 Interim Analysis  
No interim analysis is planned.   However, a fter completi on of  Part 1  of the study , the plasma and 
CSF samples will be analyzed  unblinded  for the biomarkers  to determine if changes are needed 
to the bio markers to be measure d in Part 2 .  Since the c onduct of the study in Part 2 will be 
identical to the conduct of the study in Part 1, recruitment will continue uninterrupted.  The only 
potential change between Part 1 and Part 2 are the biomarkers to be  measured.  Due to COVID -
19 potentially causing recr uitment challenges, at the time of intended analysis , Part 1 data may 
be analyzed should only 1 of the 2 cohorts in Part 1 be complete (e.g. , 14 PD Patients, 5 AD 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 29 of 58 Patients). Only the full cohort would be u nblinded, any patients not analyzed as part of the Part 1 
analysis will be analyzed when that cohort is fully completed. Full details of all analyses will be 
detailed in the SAP.   
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 30 of 58 7 STUDY DRUG AND CONCOMITANT MEDICATIONS  
7.1 Name and Description of IP and Compa rator  
Posiphen will be prepared in 5 mg, 10 mg, 20 mg, 40mg, and 80 mg HPMC hard capsule  shells .  
Matching Placebo capsules  (non-lactose compound)  will be prepared with an inert inactive 
excipient generally recognized as safe for human pharmaceutical use.   
7.2 Dosage  
The study drug is to be taken orally;  one caps ule, once a day in the morning , with or without 
food, for 25 days ± 2  days at home  (dependin g on when the confinement visit is scheduled ).  
Participants must take 80% of all doses (across 25±2 days).  Bottles  will be examined  in clinic  at 
the pre -confinement visit  to assess compliance overall and in the last week .  
7.3 Packaging/Dispensing/Labeling  
The study drug ( Posiphen  capsules  and placebo capsules ) will be manufactured under cGMP, in 
a manner to preserv e the blind, i.e., identical color and shape opaque HPMC hard capsule shells  
and packaged 30 capsules per bottle .  
The investigational drug supply  will be shipped directly  to the clinical sites to dispense to 
participants .  
The dosing schedule and storage requirements will be clearly explained to the partici pants and 
caregiver before dispensing the study drug , and it will be printed on the labels.  
All clinical trial material dispensed under this protocol will bear the requis ite cautionary 
statement “CAUTIO N: Limited by Federal (United States) Law to Investigational Use Only”.  
7.4 Storage  
Both Posiphen capsules and the matching placebo capsules  must  be stored at room temperature 
(15-30 °C; 59 -86 °F), protected from moisture, in a locked , temperature -controlled  area with 
restricted  staff access.  
7.5 Drug Accountability  
The investigator is responsible for investigational product reconciliation and records 
maintenance.  In accordance with all applicable regulatory requirements, the investigator or 
designated site staff  must maintain investigational product accountability records throughout the 
course of the study.  The responsible person(s) will document the amount of investigational 
product dispensed to and returned by subjects.  All use d and unused study drug containe rs must 
be returned to the site for accountability.  Once authorized by a clinical monitor, unused study 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 31 of 58 drug (including partially used bottles ) may be destroyed on site per appropriate site SOPS or 
should be shipped back to the Sponsor  for destruction.   
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 32 of 58 7.6 Compliance  
Site personnel will assess c ompliance based on the amount of study drug dispensed to and 
returned by the participants , together with any related information, including the administration 
of study drug by study staff during the confinement visit. Participants must take 80% of all doses  
at home  (25±2 days) depending on the confinement visit date . Site personnel will count capsules 
and eva luate compliance from the bottle at the pre -confinement visit.  
Prior to the pre -confinement visit, site personn el will also contact the participant and study 
partner to remind them of the dose regimen, to ensure that the necessary level of compliance has 
been achieved to continue with the confinement visit procedures.  
Site personnel will assess compliance at the pre-confinement visit and again at  the time of 
admission for the c onfinement v isit. If participants are found to be < 80% compliant  the site must 
consult with the Project Directors and/or Medical Monitor  regarding timing and conduct of the 
confinement visit procedures. It is possible that subjects will be discontinued early from the 
study d ue to insufficient drug compliance.  
7.7 Breaking  the Blind  
Only in the case of an emergency, when knowledge of whether the participant  has received the 
investigational produ ct is essential for the clinical management or welfare of the participant , may 
the investigator request to unblind  a participan t’s treatment assignment. If the investigator needs 
the blind to be unmasked for a subject for any reason, the investigator must contact the Medical 
Monitor and/or Project Directors  to obtain an approval. If the blind is broken,  whether it be by 
acciden t or for the welfare of the participant , the investigator MUST  contact the Medical 
Monitor.   Refer to the study procedures manual for detailed procedures related to breaking the 
blind and reporting . 
7.8 Overdose  
No specific antidote for the overdose of  Posiphen is known; however, signs or symptoms of 
possible overdose should be noted and treated .  The Medical Monitor and Project Directo rs 
should be notified as well. Because strategies for the management of overdose are continually 
evolving, it is advisa ble to contact a poison control center to determine the latest 
recommendations for the management of an overdose of any drug.  Although P osiphen is a weak 
AChE inhibitor, based upon overdose information published in prescribing information fo r 
related products, overdose  with AChE inhibitors can result in cholinergic crisis characterized by 
severe nausea, vomiting, salivation, sweating, brad ycardia, hypotension, respiratory depression, 
collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if 
respiratory muscles are involved.  Tertiary anti -cholinergics such as atropine may be used as an 
antidote for ove rdosage. Intravenous a tropine sulfate titrated to effect is recommended.  Atypical 
responses in blood pressure ( BP) and HR have been reported with other cholinomimetics when 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 33 of 58 co-administered with quaternary anticholinergics such as glycopyrrolate.  It is no t known 
whether dialys is (hemodialysis, peritoneal dialysis, or hemofiltration) is an effective treatment 
for overdose.  
7.9 Concomitant Medications  
7.9.1  Prohibited Concomitant Medications  
Current use of anti -coagulants (e.g., warfarin (Coumadin), dabigatran (Pradax a) or anti -platelet 
drugs (e.g., Plavix )see section 12.1.1 , other than aspirin up to a dose of 325  mg per day, is 
prohibited.  Prospective subjects who in consultation with the prescribing physician  can safely 
discontinue these medications for 4 weeks before screening  and remain off these medications 
throughout the study , can be considered for inclusion in the study .    
Use of the following medications is prohibited within 4 weeks of screening and throughout the 
study : 
• tricyclic antidepressants   
• antipsychotics  prescribed for any reason, except ≤50 mg quetiapine daily, risperidone 
≤1.5 mg/day, olanzapine ≤5 mg/day, and aripiprazole ≤10 mg/day  
• psychostimulants  
Investigational agents are prohibited 4 weeks  prior to entry and for the duration of the trial.  
Initiatio n of prohibited medications during the course of the study is discouraged, however, if an 
excluded medication is initiated after scree ning, the site should consult with the Project Directors 
and Medical Monitor for further guidance.  
7.9.2  Permitted Concomitant M edications  
This protocol allows concomitant treatment with  anti-parkinsonian medications  at stable doses 
for 4 weeks or greater prior to screening  and with  cholinesterase inhibitors and/or memantine if 
on a stable dose  (FDA approved drug ranges)  for at lea st 12 weeks prior to screening . 
Anticonvulsant medications  used for epilepsy or mood stabilization; neuropathic pain 
indications . Dosing  must be stable  for at least 4 weeks prior to Screening.  
Mood-stabilizing psychotropic agents , includ ing but not limited to lithium . Dosing  must be 
stable for at least  4 weeks prior to Screening.  
Use of short acting benzodiazepines  and hypnotics  for treatment on an as -needed basis for 
insomnia or daily dosing as anxiolytics is permitted but  should be avoided for 8 hours before 
administration of cognitive tests. If sedating medication is given for any short -term use, then all 
cogniti ve assessments must be administered at least 24 hours after administration of the sedative.   
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 34 of 58 8 STUDY POPULATION  
Participants in this study must be in accordance with the criteria specified below. Subjects who 
do not meet a ll inclusion criteria, disease diagn ostic criteria, or who meet any exclusion criteria 
may not be randomized into the study without prior approval from the Project Directors and 
Medical Monitor.   
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 35 of 58 8.1 Inclusion Criteria  
Subjects must meet the following criteria :  
1. Male or female aged 45 years and over. 
2. Female participants must be of non -childbearing potential or post-menopausal for at least 
2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy or bilateral 
oophorectomy) for at least 6 months prior to screening.  
3. Female participants will be given a urine pregnancy test at the screening v isit for which 
they should test n egative .  
4. A) AD  - CDR  = 0.5 or 1.  
 B) PD  - Hoehn & Yahr  ≤ 4; PD criteria by  MDS -UPDRS . 
5. A) AD  MMSE score between the range of 18 to 28. 
B) PD  MMSE score between the range of 18 to 30.  
6. General cognition and functional performance sufficiently preserved that the subject can 
provide written informed consent.  
7. No evi dence of current suicidal ideation or previous suicide attempt in the past month as 
evaluated in the Columbia Suicide Severity Rating Scale.  
8. MRI scan  within the 12 months prior to screening without evidence of infection, 
infarction, or other focal lesions and without clinical symptoms suggestive of intervening 
neurological disease. Lacunes that are not believed to contribute to the subject's cognitive 
impairment are permissible. If there is no MRI available within a 12-month timeframe, 
then an MRI must be p erformed as part of the screening procedures for eligibility.   
9. Stability of permitted medications  prior t o screening .  
a. Stable for at least 12 weeks: Cholinesterase inhibitors and/or memantine 
medication   
b. Stable for at least 4 weeks:   
i. Anti-parkinsonian medication  
ii. Anticonvulsant medicatio ns used for epilepsy or mood stabilization ; 
neuropathic pain indications  
iii. Mood -stabilizing psychotropic agents, including , but not li mited to, 
lithium.  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 36 of 58 10. Adequate visual and hearing ability (physical ability to perform all the study 
assessments).  
11. Good general health with no disease expected to interfere with the study.  
12. Subjects previously exposed to Posiphen may be included in  the study.  
8.2 Exclusion Criteria  
Subjects meeting any of the following criteria must not be included in the study:  
1. Has a history of a psychiatric disorder such as schizophrenia, bipolar disorder or major 
depression according to the criteria of the most curre nt version of the Diagnostic and 
Statistical Manual of Mental Disorders  (DSM ). Mild depression or history of depression 
that is stable on treatment with a SSRI or SNRI medication at a stable dose is acceptable.  
2. History of a seizure  disorder.  
3. Has a history or current evidence of long QT syndrome, Fridericia’s formula corrected 
QT (QTcF)  interval ≥ 450ms , or torsades de pointes . 
4. Has bradycardia (< 50 bpm) or tachycardia (>100 bpm) on the ECG at screening.  
5. Has uncontrolled Type -1 or Type -2 diabetes  . A Subject with HbA1c levels up to 7.5% 
can be enrolled if the investigator believes the subject’s diabetes is under control.  
6. Has clinically significant renal or hepatic impairment.  
7. Has any cl inically significant abnormal laboratory values. Subjects with l iver function 
tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than 
twice the upper limit of normal will be excluded.  
8. Is at imminent risk of self -harm, based on clinical interview and responses on the C 
SSRS, or of harm to  others in the opinion of the Investigators. Subjects must be excluded 
if they report suicidal ideation with intent, with or without a plan or method (e.g. positive 
response to Items 4 or 5 in  assessment of suicidal ideation on the C SSRS) in the past 2 
months, or suicidal behavior in the past 6 months.  
9. Has four or more signal hypointensities on T2* -weighted gradient recalled echo magneti c 
resonance sequences that are thought to represent hemosiderin deposits including 
microhemorrhages and superficial siderosis  or evidence of acute or sub -acute micro or 
microhemorrhage as noted on the MRI scan . 
10. Has c ancer or has had a malignant tumor withi n the past year, except patients who 
underwent potentially curative therapy with no evidence of recurrence. (Patients with 
stable untreated prostate cancer or skin cancers are not excluded).  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 37 of 58 11. Alcohol / Substance  use disorder , moderate to severe , in the last  5 years according to the 
most current version DSM . 
12. Participation in another clinical trial with an investigational agent and have taken at least 
one dose of study medication,  unless unblinded on placebo , within 60 days  prior to  the 
start of  screening. (Th e end of a previous investigational trial is the date the last dose of 
an investigational agent  was taken ), or five half -lives of the investigational drug, 
whichever is greater . 
13. Subjects with infection or inflammation of the skin or skin diseas e at or in p roximity to 
the lumbar puncture site.  
14. History of lumbar spine surgery or chronic low back pain (CLBP).  
15. Subjects with learning disability or deve lopmental delay.  
16. Subjects whom the site PI deems to be otherwise ineligible . 
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 38 of 58 9 DESCRIPTION OF STUDY VISITS  
Each subject will have a  42-day screening period followed by 25±2 days of treatment  at home . 
The study visits are described below and outlined in the Schedule of Events in Appendix 1 .  
9.1 Screening Visit  
The screening visit should occur up to 42 day s before the baseline visit. The screening visit 
procedures may be completed over multiple days .  
Potential participants, or legally authorized representatives, and their study partners must sign an 
informed con sent form prior to administration of any stud y-related procedures. Information 
regarding the subject’s demographics, concurrent medications, and medical history will be 
collected  along with cognitive assessments , physical examination, and neurological exam ination . 
Safety assessments will include an MRI scan  (up to 12 months prior)  and ECG that will need to 
be read locally  and reviewed  by the site investigator  to confirm eligibility . The clinical safety 
laboratory  blood  and urine  tests will be sent to a central lab for analysis . The screening s afety 
laboratory tests will be comprise d of a metabolic panel, complete blood count,  coagulation panel,  
and urinalysis as listed in Section 12.1.3 . Coagulation panel results must be obtained prior to 
performing the lumbar puncture.  Urine dipstick pregnancy  test will be completed for female 
subjects.  
Cognitive and functional assessments should not be administered when the s ubject is in a fasted 
state. Once all s creening visit procedure s are completed, all information related to eligibility, 
including screening lab results, must be reviewed by the site investigator to assess the su bject’s 
eligibility before proceed ing to Baseline.  
Sites should try to enroll patients who already have an M RI scan available to limit patient 
burden. Any patient who requires a new MRI must  have all other screening assessments 
completed prior to  performing  the MRI.  
9.2 Baseline Visit  
Baseline procedures include functional, c ognitive, and behavioral assessments, sa fety 
assessments, and review of concurrent medications and adverse events that occur in clinic.  
Following completion of all baseline proc edures, subjects who continue to meet all protocol 
inclusion criteria and no exclusion criteria, should be scheduled f or the confinement visit. The 
subject  should then be randomized, dispensed study drug , and instructed on proper storage and 
at-home  dosing  based on the scheduled date of the confinement visit . The subject should be 
instructed on  1.) to take the first dose immediately after the baseline spinal tap and venipuncture  
2.) the Day 14 Contact  and the  Pre-Confinement Phone Contact  and 3.) Study d rug compliance 
and study drug return .  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 39 of 58 A lumbar puncture will be performed as part of the baseline  visit, in the morning  (before 10 am 
is rec ommended), a fter an overnight fast.  After the collection of the baseline lumbar puncture 
and venipuncture , the first dose of Posiphen will be administered to the patient . 
The subject will stay at the unit for a  1 hour observation period and may  be safely discharged to 
home per investigator discretion .  Subjects will have the option to stay overnight in the 
occurren ce of adverse events associated with the LP procedure.  
Subject baseline visi t can be split over two (2) consecutive  days should the investigator feel that 
the neuropsychological tests are better complete d without fatigue (i.e. , after LP or unfasted).  
9.3 Day 14 Telephone Contact  
A telephone call w ill be conducted at 14 ± 4 days from the baseline visit to assess for any 
changes in status, adverse events, or concomitant medications. Study medication compliance will 
be discussed,  and reminders given ab out the upcoming confinement visit . If there is an  
insufficient level of drug compliance (less than 80% overall ), the site must consult with the 
Project Directors and Medical Monitor regarding timing and conduct of the remaining 
confinement visit procedure s. It is possible that subjects will be discontinu ed early from the 
study due to insufficient drug compliance.  
9.4 Confinement Visit  
Admission for the confinement visit sho uld occur  25 ± 2 days following the first dose of study 
medication. A pre-confinem ent phone call  will be conducted 1 -3 days prior to admission and a 
post-confinement p hone follow -up will be conducted approximately 24 hours following 
discharge.  Confinement  procedures include functional, cognitive, and behavioral assessments, 
safety assessments, and rev iew of concurrent medications and adverse events that occur in clinic , 
blood and CSF collection .  
9.4.1  Pre-Confinement Telephone Contact   
A telephone  call will be conducted at 1 -3 days prior  to confinement to assess  for any changes in 
status, adverse events, or concomitant medications.  Study medication compliance will be 
discussed, and reminders given about the upcoming conf inement visit . If there is an insufficient 
level of  drug compliance  (less than 80% overall) , the site must consult with the Project Directors 
and/or Medical Monitor regarding timing and conduct of the Confinement Visit procedures. It is 
possible that subjects will be discontinued early from the study due to insufficient compliance.  
9.4.2  Confinement Visit  
The confinement visit will consist of the following : admission  procedures , Time 0 blood and 
CSF sampling, administration of  last dose  of study drug, 6-hours of blood and CSF  sampling, at 
least a 1-hour observation  period  while subject remains on bed rest with the observation period 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 40 of 58 to be extended as clinically necessary as per the Investigator’s decision , and discharge  
procedures . Subjects will be provided with sleeping accommodations during t his visit , if 
necessary , and maybe permitted to remain overnight per investigator discretion i n the event there 
are adverse events associated with the study medications or study procedures .  
 
Subject confinement visit can be split over two  (2) consecutive  days should the investigator feel 
that the neuropsychological tests are better complete d one day before the lumbar puncture .   
Period  1: Admission  
Subjects should arrive fasted in the early morning af ter an overnight fast.  Clinical safety labs will 
be drawn and sent to the central  lab for analys is.  
Study d rug c ompliance over the pr eceding days will be assessed. If there is an insufficient level 
of drug compliance  (less than 80% overal l), the site must  consult with the Project Directors and 
Medical Monitor) regarding timing and conduct of the remaining confinement visit procedures. 
It is possible that subjects will be discontinued early from the study due to insuff icient  study drug 
compliance.  
Admission  visit procedures include  conducting a Physical and Neurological Exam , administering 
functional and cognitive  evaluations and C -SSRS, collecting v ital signs , ECG , clinical labs , 
reviewing and recording a dverse events and concurrent medications . 
Perio d 2: 6-Hour Sampling  
If no medical or compliance concerns are identified during the admission procedures, the subject 
will move on to the 6-Hour Sampling Phase, which entails the following procedures:  
1. Place an intravenous line for blood  sampling .  Alternatively, blood may be sampled by 
direct venipuncture if deemed appropriate by the PI.   
2. Place the CSF catheter .  
3. Collect initial samples of blood and CSF  (Hour 0) . 
4. Administer last dose of assigned study drug after the  0 hour sampling . 
a. Collect CSF  (6 mL)  and blood (10mL) every hour at the following time points: 1, 
2, 3, 4, 5, 6 hours . 
i. CSF and blood should be taken within ± 10 mins of hourly times . 
ii.  If unable to obtain a total of 6 mL CSF at any given collection time (e.g. 
due to participant headache or participant’s CSF productio n level), reduce 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 41 of 58 the collection volume to a tolerated amount (minimum 2mL). If there  is 
poor flow at any of the time points, then the next collection could be 
skipped to allow for better flow at the subsequent collection time. For 
example, if less than 2mL  of CSF is collected at the 1 -hour time point, 
then the 2 -hour CSF collection could be skipped, and CSF collection 
would resume at the 3 -hour time point.  
b. Perform periodic safety monitoring  during the collection period . This includes 
questions  about any symptoms  in relation to the CSF catheter (inclu ding potential 
adverse events such as leg or back pain, dizziness or headaches) and vital sign 
monitoring.  Participants also should be asked about pain, red ness or swelling at 
the blood collection  site in the arm.  
c. Subjects remain on bed rest throughou t the CSF sampling period of 6 hours. They 
are allowed to use a bedside commode for toileting.  
5. After  the final  6-hour blood and CSF samples  have been collected, remove the blood 
collection line and LP catheter . 
6. Perform final safe ty monitoring , a physical , and a neurological exam. 
The site should complete the LP catheter via their local practice/ procedures;  however , sites can 
refer to the LP catheter supporting documentation which will be provided.  
If the subject exp eriences intolerable AE(s) that require early discontinuation of the sampling 
procedures and remov al of the LP catheter, contact the Medical Monitor and Project Directors as 
soon as poss ible to discuss the situation. If feasible, the standard 6-hour observ ation and 
discharge procedures should be followed to allow for management and follow -up on the adv erse 
events.   
Period  3: Observation  
The subject should be observed for at least 1 hour followi ng removal of the LP catheter .  The 
subject should remain on bed rest during this 1 hour follow up .  
A blood patch will be administered as required if a subject exhibits signs of a post-spinal tap 
headache that is not managed with  bed rest, oral and intrave nous fluids,  caffeine, and/or mild 
analgesics (e.g., Ibupro fen, N aproxen or Tylenol).  All unused study drug should be returned to 
the clinical site for final accountability.   
Subjects may be permitted to stay overnight in the event there are ongoing adverse events that 
require monitoring per investigator discretion.  
 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 42 of 58 Period  4: Discharge  
Prior to discharge, vital signs should be recorded,  and a review of AE (s) and Concurrent 
Medications should be conducted. Upon determ ination by the investigato r (or qualified designee) 
that the subject is stable, the participant will be discharged.  If a participant experienc es an 
unstable AE, please contact the Medical Monitor and Project Directo rs for guidance on the 
appropriate  course of action to be taken.  
9.4.3  Post-Confinement 24 -Hour Phone Follow -up 
Approximately 24  hours following discharge from the Confinement Visit the subject or a person 
designated to speak for them will be contacted by phone to confirm the subject’s well -being and 
to query about any new AEs.  
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 43 of 58 10 EARLY TREATMENT/STUDY DISCONTINUATION  
The investigators  at each site will make every reasonable effort to maximize subject retention. 
However, if an investigator removes a subject from treatment or study, or if a subject declines 
further treatment or st udy participation, an early discontinuation visit will be completed as soon 
as possible following discontinuation. The early discontinuation visit will contain the same 
assessments  as the confinement  (admission)  visit. If an in -person visit is not possible , site 
personnel will complet e as much of the early discontinuation visit as possible by telephone.  
Subjects who discontinue from the study prior to completing all protocol procedures  may be 
replaced at the discretion of the Coordinating Center, in consult ation with the Sponsor.  
10.1 Reaso ns for Early Discontinuation  
Participant s may withdraw from the study at any time as stated in the informed consent 
document given to the participant  at the time of enrollment. Participant s may also be 
discontinued from treatme nt/study for reasons such as the following:  
• Adverse experience: The participant  has experienced an adverse event that, in the opinion 
of the investigator, requires early termination. This may include abnormal laboratory 
values.  
• Death . 
• Safety risk: Any participant  who becomes a safety risk to themselves  during the trial will 
be withdrawn.  
• Protocol violation: The participant  fails to meet protocol entry criteria or d oes not adhere 
to protocol requirements.  
• Non-compliance: The participant  is non -compliant with  completion of study -related 
evaluations and / or intake of study drugs.  
• Development of suicidal or homicidal ideation requiring hospitalization or confinement . 
• Consent is withdrawn. The participant  wishes to withdraw from the study, o r the legally 
authoriz ed representative wish es that the participant  be withdrawn.  
• The study is terminated by the Sponsor/Coordinating Center, alone or at the 
recommendation of the Data Safety Monitoring Board.  
• Lost to follow up.  Participant  could not be recalled back to conduc t follow up visits.  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 44 of 58 11 STUDY -SPECIFIC INSTRUMENTS  
We are planning a number of tests that measure states of function, depression, dementia, memory 
and attention .  Those measures include minimally the following:  
PD: MMSE, WAIS-IV, MDS -UPDRS  
AD: MMSE, WAIS -IV, ADAS -Cog 14 , CDR  
12 STUDY -SPECIFIC PROCEDURES  
12.1 Safety Assessments  
Safety will be evaluated by  monitoring for  changes in the parameters summarized below, 
including any A Es/SAEs as reported by subjects or observed by the clinical staff, or by the use of 
concomi tant medication during the study.  
12.1.1  Physical and Neurological Examination  
A medically qualified professiona l will perform a physical examination that consists of a review 
of the major body systems (i.e., skin, head/ears/eyes/nose/throat (HEENT), cardio vascular, 
pulmonary, abdomen, musculoskeletal, and extremities) and a neurological examination whic h 
will include an assessment of cranial nerves, strength, coordination, reflexes, sensation, t remor, 
gait and mental status. Assessments of height, wei ght, and vital signs (systolic and diastolic 
blood pressure, pulse, temperature, and respiration) are inc luded.  
12.1.2  Electrocardiogram (ECG)  
An appropriately qualified individual will conduct a  standard 12 -lead supine resting ECG. The 
ECG report must  be reviewe d, signed, and dated by the site PI (or a medically qualified  
individual d elegated by the  site PI). Those with clinically significant ECG findings will be 
referred for follow -up as deemed appropriate by the investigator and may be excluded from the 
study.  
12.1.3  Clinical Laboratory Evaluations  
Blood and urine samples will be obtained for clinical safety l ab assessments as described in the 
Schedu le of Events  (Appendix 1 ).  The following table lists the clinical safety lab tests that will 
be assessed by the central lab at three time points : the screening visit , the pre -confinement visit, 
and the end of the 6-hour sampling period .  Refer to the Laboratory Manual for additional 
details.  
 
CLINICAL SAFETY LAB TESTS  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 45 of 58 Lab reports will be reviewed, signed and dated by the site PI (or a medic ally qualified  individual 
delegated by the PI). If a value is outside of the laboratory’s normal range, the clinician will 
indicate if the value has clinical  significan ce. Those results that are deemed clinically signifi cant 
may need to be repeated and may require follow up with the subject’s primary care physician for 
further evaluation .  
12.2 Biofluids  
12.2.1  CSF for Biomarkers  
Standard Lumbar Puncture  (LP) : 
A LP will be performed as part of the baseline visit, in t he morning (before 10 am is 
recommended), after an overnight fast.    
Participants taking an  anti-platelet agent (e.g. Plavix ) must be discontinued from that agent for a 
minimum of 5 days prior  to the lumbar puncture. These participants may continue with the agent 
after a minimum of 24 hours post LP. Participants who are taking anticoagulants (e. g. warfarin 
(Couma din) and/or dabigatran (Pradaxa ) may not undergo an LP and are not suitable to 
participate in this study.  
Each study participant or a person designate d to speak for them will be contacted by phone 
approximately 24 hours after the LP to confirm partici pant well -being and any adverse events.  
CSF Catheter Sampling:   
CSF should be collected at each timepoint during the CSF catheter sampling . At hours 0,  1, 2, 3, 
4, 5, 6 (± 10min) , each 6 mL of CSF is collected . METABOLIC PANEL  COMPLETE BLOOD COUNT  URINALYSIS  
Sodium  (Na) 
Potassium (K)  
Chloride (Cl)  
Carbon Dioxide (CO2)  
Blood Urea Nitrogen (BUN)  
Glucose  
Calcium (Ca)  
Creatinine (Crn)  
Bilirubin Total  
Albumin  
Protein (NOS) Total  
Glutamic -OxaloaceticTransferase 
(AST, SGOT)  
Glutamic -PyruvateTransferase 
(ALT, SGPT)  
Alkali ne Phosphatase NOS  White Blood Cell Count (WBC)  
Red Blood Cell Count (RBC)  
Hemogl obin (Hb)  
Hematocrit (HCT)  
Mean Corpuscular Volume (MCV)  
Mean Corpuscular Hemoglobin (MCH)  
Mean Corpuscular Hemoglobin  
Concentration (MCHC)  
Red Blood Cell Distribution Width ( RDW)  
Mean Platelet Volume (MPV)  
Platelet Count (PLT)  
 
 Color  
Appearance  
Specific Gravity  
pH 
Blood  
Glucose  
Protein  
Ketones  
Leukocyte Esterase  
Nitrite  
Urobilinogen  
Bilirubin  
 
COAGULATION PANEL  
PPT/PTT  
[Screening Visit ONLY]  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 46 of 58 NOTE: The final dose of study drug should be given after  the 0 hour sample but before  the 1 
hour sample   
NOTE : If unable to obtain a total of 6  mL CSF at any given collection time (e.g. due to 
participant headache or participant’s CSF production le vel), reduce sampling size and obtain the 
maximum tolerated amount  (minimum 2m L). If unable to obtain a total of 6 mL CSF at any 
given collection time (e.g. due to participant headache or participant’s CSF production level), 
reduce the collection volume to  a tolerated amount (minimum 2mL). If there is poor flow at any 
of the time points, then the next collection could be skipped to allow for better flow at the 
subsequent collection time. For example, if less than 2mL of CSF is collected at the 1 -hour time 
point, then the 2 -hour CSF collection could be skipped, and CSF collection would resume at the  
3-hour time point . 
To clear blood associated with needle insertion, the first 1 -2 mL (or more if needed) of CSF will 
be discarded.   Refer to the CSF Manual for additional details.   
Each study participant or a person designated to speak for them will be contacted by phone one 
day after being discharged  from the confinement visit. The p articipant  will be asked about their 
wellbeing  and the occurrence of any adverse events.  
12.2.2  APOE Genotyp e and other DNA Markers  
DNA will be extracted from participant blood samples at the baseline  visit and will be analyzed 
for APOE genotype. This will allow secondary analyses of data on the impact of the APOE 
genotype o n putative biomarkers of AD, clinical outcome measures, and adverse events. APOE 
polymorphisms are an important genetic risk factor for AD. Individuals with one or two 
Apolipoprotein epsilon 4 ( APOE4 ) alleles have a higher risk of developing AD and an earl ier 
age of onset. Furthermore , those with one or two APOE4 alleles exhibit a more rapid rate of 
clinical change in some, but not all studies.  
Blood is collected in a uniform fashion using EDTA as anti -coagulant, as described in the 
Laboratory Manual .  Par ticipants will be asked to co nsent to optional DNA banking for future 
research studies.  
12.2.3  Plasma for Biomarkers and Pharmacokinetics  
Plasma samples will be collected at the baseline  visit and during the confinement visit every hour 
for analysis of biomarkers , inflammatory factors, dopamine,  acetyl choline and drug level 
analyses.  
Biomarker and PK analyses sample collection  will be performed on the 10 m L EDTA plastic 
tube whose collection is described in the Laboratory Manual .    
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 47 of 58 12.2.4  Blood Samples for Exosomes  
Blood will be collected in the morning, after an overnight fast, in EDTA tubes and will be 
subjected to two sequential centrifugations to generate platelet -poor plas ma within one hour from 
the blood draw , as described in the Laboratory Manual.  Note  - for exosomes draws at the 
confinement visit  after the 0-hour sample, strict fasting is no longer required. Low lipid foods 
(e.g., apple, banana, bread)  are allowed.  
13 PERSONNEL REQUIREMENTS  
The site PI is responsible for the overall con duct of the study at the site. The PI is to supervise 
project personnel  and ensure that clinical raters maintain a high level of skill and accuracy in 
conducting assessments. Additionally , the PI will perform or supervise clinical evaluation of all 
subject s and ensure protocol adherence. Additional key personnel will be requi red, as outlined in 
the procedure manual.   
14 ADVERSE EVENTS  (AEs)   
14.1 Definition  
An AE is defined as per the US Code of Federal Regulation, Title 21, Part 312.32 
[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32 ]. An AE is any 
untoward medical occurrence associated with the use of a drug in hu mans, whether or not 
considered drug related.  
Collection of adverse events will begin once infor med consent is signed and will continue until 
the follow -up phone call performed on the day after discharge.  Adverse events include but are 
not limited to: (1)  worsening or change in nature, severity, or frequency of conditions or 
symptoms present at the start of the study; (2) Subject deterioration due to primary illness; (3) 
intercurrent illness; and (4) drug interaction. An abnormal laboratory value will only  be reported 
as an AE if the investigator considers it clinically  significant, or if it leads to  the Subject being 
withdrawn from the study.  
The investigator should attempt to establish a diagnosis of the event based on signs, symptoms, 
and or other clinic al information. In such cases, the diagnosis should be documented as the AE 
and not the individu al signs or symptoms. Symptoms and conditions present at the beginning of 
the study will be characterized, so that A Es can be defined as any new symptom, or any  increase 
in frequency or severity of an existing symptom. Adverse events should be described wi th 
medical terminology so that the event can be matched against a medical coding dictionary, such 
as MedDRA (Medical Dictionary for Regulatory Activities).  
Investigators should report their assessment of the potential relatedness of each AE to the 
protocol  procedure, and to the investigational product, and/or drug delivery system used in the 
protocol.   
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 48 of 58 Following questioning and evaluation, all A Es, whether determ ined to be related or unrelated to 
the study drug by a medically qualified site PI or clinician must be documented in the Subject’s 
records, in accordance with the investigator’s normal clinical practice, and on the AE electronic 
case report form ( eCRF ). 
14.2 Following Up on A Es 
The investigator is obliged to follow subjects with A Es until the events have  subsided, the 
conditions are considered medically stable, or the subjects are no longer available for follow up. 
Subjects who discontinue due to adverse experi ences will be treated and followed according to 
established medical practice. All pertinent info rmation will be entered into the eCRF. Adverse 
events will be reported to the Medical Monitor, Sponsor, and  DSMB , per Coordinating Center 
SOPs and the DSMB Char ter. 
Because of the potential of additive cholinergic adverse events caused by a combination of 
Posiphen and cholinesterase inhibitors in some subjects , the severity of such adverse events 
should be carefully evaluated taking the criteria in Appendix 2 into consideration (modified from 
CTCAE version 4.03.)  
15 SERIOUS ADVERSE EVENTS (SAE)  
15.1 Definition  
A SAE is defined as per the US Code of Federal Regulation, Title 21, Part 312.32 
[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32 ]. 
An adverse event or suspected adverse react ion is considered “serious ” if, in the view of either 
the investigator or Sponsor, it results in any of the following outcomes: Death, a life -threatening 
adverse event, inpatient hospitalization or prolongation o f existing hospitalization, a persistent or 
significant incapacity or substantial disruption of the ability to conduct normal life functions, or a 
congenital anomaly/birth defect. Important medical events that may not result in death, be life -
threatening, or require hospitalization may be considered  serious when, based upon appropriate 
medical judgment, they may jeopardize the Subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such medical 
events include allergic bronchospasm  requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.  
15.2 Reporting SAEs  
Collection of serious adverse events will b egin once informed consent is signed (regardless of 
study drug exposure) and will continue until 30 days following the last dose of study drug .  All 
SAEs  must be reported to the Medical Monitor, the Sponsor, Project Directors and the 
Coordinating Center wi thin 24 hours of learning of the event. This in turn will trigger an alert to 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 49 of 58 the appropriate Coordinating Center personnel and Protocol Project Directors, which will lead to 
the initiation of the creation of the  report. A notification will be sent to all participating sites and 
the DSMB once the report is available. Sites will inform their IRB of the event based on local 
IRB requirements. The Sponsor is the IND holder  and is responsible for submitting any SAEs 
according to the FDA reporting requirements.  
16 DATA AND SAFETY MONITORING BOARD  (DSMB)  
A DSMB will review the safety information from the study  on an ongoing basis. The DSMB, 
will identify the study -specific data parameters and format of the information to be reported , as 
well as the timing of reports based on the enrollment status of the study . The DSMB will initially 
be provided with data blinded to treatment status, but they may request unblinded  data if there is 
a safety concern.  
Additionally, the DSMB will  be informed of the occurrence of any serio us adverse events within 
7 days of being reported to the Coordinating Center. The DSMB may at any time request 
additional information from the Coordinating Center.  
Based on the review of safety data, the DSMB will  make recommendations regarding the 
conduct  of the study. These may include amending safety monitoring procedures, modifying the 
protocol or consent, terminating the study or continuing the study as designed. Using the Safety 
Review Process (review of lab data, vitals, and adverse events) and the D SMB, there is 
substantial oversight and case review to alert the investigators, in a timely manner, to any  safety 
issues that may arise. Further details  will be provided in  the DSMB charter.  
17 RECORDING AND COLLECTI ON OF DATA  
17.1 Electronic Case Report Form  (eCRF) 
The PI or designee will record all data collected (either written or electronic record of data). 
Written or electronic data of record must be entered into the eCRF provided for that purpose. In 
some instances , no prior written or electronic record of d ata may exist,  and data recorded directly 
into the eCRF is considered source data. The site will be suitably trained on the use of the eCRF 
and appropriate site personnel will be authorized to provide electronic s ignatures. The PI is 
responsible to verify the integrity of the data and acknowledge as such by signature.  
All site entries will be made in a secured eCRF  and the PI will revie w the record for 
completeness. If corrections are necessary to the eCRFs, the PI or designee will update the eCRF 
and provide documentation for the reason for change.  
Completed eCRFs will be submitted according to provided instructions and  reviewed by the 
Coordinating Center to determine their acceptability. If necessary, data correct ion requests will 
be generated for r esolution by the study site.  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 50 of 58 17.2 Study Files and Source Documents  
Subject confidentiality is strictly held in trust by the participating investigators, research staff, 
and the Coordinating Center and/or sponsoring  instituti on and their agents. This confidenti ality is 
extended to cover testing of biological samples and genetic tests in addition to the clinical 
information relating to subjects.  
The study protocol, documentation, data and all other information generated will be  held in strict 
confidence. No infor mation concerning the study,  or the data will be released to any 
unauthorized third party, without prior written approval of the sponsoring institution. Authorized 
representatives of the sponsoring institution may inspec t all documents and records required  to 
be maintained by the investigator, including but not limited to, medical records (office, clinic or 
hospital) and pharmacy records for the subjects in this study. The clinical study site will permit 
access to such re cords. Any data, specimens, forms, r eports, video/audio recordings, and other 
records that leave the site will be identified only by a subject identification number (Subject ID, 
PID) to maintain confidentiality. All records will be kept in a locked file ca binet. All computer 
entry and networking programs will be done using PIDs only. Information will not be released 
without written permission of the Subject, except as necessary for monitoring by the Institutional 
Review Board ( IRB), the FDA, and the Office for Human Research Protections ( OHRP ). 
Information about study subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act ( HIPAA ) of 19 96. 
Those regulations require a signed Subje ct HIPAA Authorization informing the Subject of the 
following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a  research subject to revoke their authorization for use of their PHI  
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to use all infor mation collected prior to the revocation of subject 
authorization. Each site PI, under the guidance of his/her IRB, is responsible for ensuring that all 
applicable HIPAA regulations and State laws are met.  
18 ETHICS AND REGULATORY CONSIDERATIONS  
18.1 Good Clinical  Practice  
This study will be conducted in co mpliance with the protocol and accordance with Good Clinical 
Practice (GCP) guidelines, as defined by the International Conference on Harmoni zation (ICH) 
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 51 of 58 Guideline, Topic E6, the United States Code of Federal Reg ulations (CFR), Title 21, Part 50 – 
Protecti on of Human Subjects, and Part 56 – IRBs,  HHS Regulations (45 CFR part 46 , 160, 164  
HHS Regulations for the Protection of Human Subjects; HIPAA; 42 CFR part 50), Subpart F 
HHS Regulations for Responsibility of Applicants for Promoting Objectivity in Resear ch for 
Which PHS Funding Is Sought  HIPAA, State and Federal regulations and all oth er applicable 
local regulatory requirements and laws.  
Study personnel involved in conducting this study will be qualified by education, training and 
experience to perform th eir respective task(s) in accordance with GCP.  
No study document shall be destroyed without prior written agreement between the Coordinatin g 
Center and the investigator. Should the investigator wish to assign study records to another party 
or move them to another location, he/she may do so only with the prior written consent of the 
Coordinating Center.  
18.2 Institutional Review Board (IRB)  
Institutional Review Boards must be constituted,  and their authority delegated through the 
institution ’s normal process of governance according to applicable State and Federal 
requirements for each  participating location. Each participating institution must provide for the 
review and approval of this protocol and the associated informed consent documents and 
recruitment materi al by an appropriate IRB registered with the OHRP. Any amendments to the 
protocol or consent materials must also be approved before they are placed into use. In the 
United States, only institutions holding a current US Federal  wide Assurance (FWA) issued b y 
OHRP may participate. Refer to: http://www.hhs.gov/ohrp/assurances/ . 
The investigator must obtain approval from the IRB for all subsequent protocol amendments and, 
when warranted, changes to the informe d consent document. Protocol and informed consent 
form amendments can be m ade only with the prior approv al of the Coordinating Center. The 
investigator may not implement any protocol deviation without prior notification , review , and 
documented approval by the Study Director , except where necessary to eliminate an immediate 
hazar d to study subjects, or when change(s) involve only logistical or administrative aspects of 
the trial. The investigator shall notify the IRB of deviations from the protocol or seriou s adverse 
events occurring at the site, in accordance with local procedure s. 
18.3 Informed Consent and Health Insurance and Portability and 
Accountability Act (HIPAA ) Compliance  
Informed consent will be obtained in accordance with 21CFR  §50.25, and ICH Good Cli nical 
Practice. Applicable HIPAA privacy notifications will be implemented,  and HIPAA 
authorizations signed before protocol procedures are carried out. Information should be given in 
both oral and written form as deemed appropriate by the Site’s IRB.  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 52 of 58 Prior  to the beginning of the trial, the investigator must  obtain  the IRB’s written approval of the 
informed consent form and any other written information to be provided to subjects and be 
acceptable by Regulatory Affairs. Consent forms  must be in a language f ully comprehensible to 
the prospective subjects and/or their authorized representatives and study partners. Subjects, their 
relatives, guardians, or authorized representatives and study partners will be given ample 
opportunity to in quire about the details of the study. Prior to a subject’s participation in the trial, 
the written informed consent form should be signed and personally dated by the subject or by the 
subject’s legally acceptable representative, and by the person who condu cted the informed 
consen t discussion. Subjects will be provided a copy of the signed ICF.  
The informed consent will not only cover consent for the trial itself, but for the genetic 
samples/data/storage and biomarker samples/data/storage as well. Consent fo rms will specify 
that DN A and biomarker samples are for research purposes only; the tests on the DNA and 
biomarker samples are not diagnostic in nature and subjects will never receive results.  
19 STUDY MONITORING   
The clinical monitor is responsible for inspe cting the case report forms  (CRFs)  and source 
documentation at specific time points throughout the study to verify adherence to the protocol, 
completeness and accuracy of the data, and adherence to local regulations on the conduct of 
clinical research.  The monitoring visits must be conducted according to the applicable ICH and 
FDA guidelines to ensure protocol adherence, quality of data, drug accountability, compliance 
with regulatory requirements and continued adequacy of the investigational site and its f acilities. 
The Site Investigator will cooperate in the monitoring process by ensuring the availability of the 
CRFs, source documents and other necessary documents at the time of the monitoring visits. Site 
Investigator will promptly address any matters bro ught to his/her attention by the monitor. The 
Site Investigator may also be asked to meet in -person with the site monitor during certain visits.  
20 AUDIT  
In accordance with ICH E6 (Good Clinical Practices) representatives of the Coordinating Center 
and/or Spo nsor and/or regulatory agency may select this study for audit. The investigator and 
study staff are responsible for maintaining the site master file containing all study -related 
regulatory documentation as outlined by Regulatory Affairs that will be suitab le for inspection at 
any time by the CRO , Sponsor, its designees, and/or regulatory agencies. Inspection of site 
facilities (e.g., pharmacy, laboratories) to evaluate the trial conduct and compliance with the 
protocol may also occur.  
21 RECORD RETENTION  
Essen tial documents and study records must be retained for a minimum of seven years following 
primary publication of study results. The Coordinating Center will notify sites when retention of 
such documents is no longer required. Essential docume nts should be retained for at least 2 years  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 53 of 58 after the last approval of a marketing application in an ICH region and until there are no pending 
or contemplated marketing applications in an ICH region or at least 2 years have elapsed since 
the formal discont inuation of cli nical development of the investigational product. These 
documents should be retained for a longer period however if required by the applicable 
regulatory requirements or by an agreement with the Sponsor. It is the responsibility of the 
Spons or to inform th e investigator/institution as to when these documents no longer need to be 
retained.  
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 54 of 58 22 LITERATURE CITED  
Berg, L. (1988). Clinical Dementia Rating (CDR). Psychopharmacol Bull,  24(4), 637 -639. 
Cullen E. et al, Geneva -Springfield Symposium pos ter (2006) . Axonyx, Brain Aβ42 in mice 
treated orally with Posiphen is significantly lower than in vehicle control.  
Folstein M.F., Folstein, S.E., McHugh, P.R. (1975). “Mini -mental state ”. A practical method for 
grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 
189-198. 
Goetz CG, Tilley BC, Shaftman SR, Stebbin GT, et al. (2008). Movement Disorder Society -
Sponsored Revision of the Unified  Parkinson’s Disease Rating Scale (MDS -UPDRS): Scale  
Presentation and Cl inimetric Testi ng Results.  Movement Disorders. Vol. 23, No. 15, pp. 2129 –
2170.  
Hoehn MM, Yahr  MD (1967).  Parkinsonism:  onset, progression, and mortality.  Neurology. 
Vol. 17. No. 5.    
Kadir A., Andreasen N., Almkvist O., Wall A., Forsberg A., Engler H., HagmanG., Lärks äter 
M.,Winblad B., Zetterberg H., Blennow K., Längström B., Nordberg A. (2008). Effect of 
Phenserine Treatment on Brain Functional Activity and amyloid in Alzheimer ’s disease . Ann 
Neurol 621 -631. 
Kuo YM, Nwankwo  EI, Nussbaum RL, Rogers J, Maccecchini  ML. Translational inhibition of 
α-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. Am J 
Neurodegener Dis 2019;8(1):1 -15 
Lahiri  D.K., Chen D. , Maloney B. , Holloway H .W., Yu Q .S., Utsuki T. , Giordano T. , 
Sambamurti K. , Grieg N. (2007) . The experimental Alzheimer ’s Disease drug Posiphen  
[(+)-phenserine] lower amyloid -β peptide levels in cell cultures and in mice. J Pharmacol Exp 
Ther 320:386 -396. 
Lilja A.M., Röjdner J., Mustafiz T., Thome C.M., Storelli E., Gonzalez D., Lithner  C.U., Greig 
N.H., Nordberg A., Marutle A. (2013) Age -Dependent Neu roplasticity Mechanisms in 
Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid -β Levels 8(3).  
Maccecchini M .L., Chang M .Y., Pan C ., John V ., Zetterberg H ., Greig N . (2012). Posiphen  as a 
candidate drug to lower CSF amyloid precursor protein, amyloid -b peptide and s levels: target 
engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry 
83:894 -902. 
Marutle A., Ohmitsu M., Nilbratt M., Grieg N.H., Nordberg  A., Sugaya K. (2007) Modulation of 
human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine . 
PNAS 104(30)  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 55 of 58 Posiphen Investigational Drug Brochure (ANNOVIS BIO, Inc., 2019).  
Schafer K, Aisen P., et al. (2012). Admini stration  and Scoring Manual  Alzheimer’s Disease 
Assessment Scale – Cognitive (ADAS -cog). A Publication of the Alzheimer’s Disease 
Cooperative Study.  
Teich AF, Sharma E, Barnwell E, Zhang H, Staniszewski A, Utsuki T, Padmaraju V, Mazell C, 
Tzekou A, Samba murti K,  Arancio O, Maccecchini ML. Translational inhibition of APP by 
Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. 
Alzheimers Dement Transl Res Clin Interv 2018;4:37 –45. doi:10.1016/j.trci.2017.12.001. 
PMCID: PMC6021259  
Yu QS1, Reale M, Kamal M .A., Holloway H .W., Luo W ., Sambamurti K ., Ray B ., Lahiri D .K., 
Rogers JT, Greig NH. (2013). Synthe sis of the Alzheimer drug Posiphen into its primary 
metabolic products (+)-N1-norPosiphen, (+) -N8-norPosiphen and (+) -N1,N8 -bisnorPosiphen, 
their inhibit ion of amyloid precursor protein, a Synuclein synthesis, interleukin -1β release and 
cholinergic action. Antiinflamm Antiallergy Agents Med Chem. 12:117 -28. 
 
  
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 56 of 58 23 APPENDIX 1: SCHEDULE OF EVENTS   
Visit Timinga Day -42 to 0  Day 14 
(± 4) 1-3 days prior 
to confinem ent Days 25 ( ± 2) 
Procedures  Screening  Baseline  Phone  Pre- 
Confinement 
Phone 
Contact  Confinement  
Admission  6-Hour 
Sampling  Dischargee 
Informed Consent  X       
Demographics  X       
Medical and Psychiatric History  X       
Height and BMI  X       
Inclusion and Exclusion Criteria  X X      
Urine Dipstick  Pregnancy Test  X       
Physical and Neurological 
Examination X X   X  X 
AD & PD:  MMSE  X X   X   
AD:  CDR  X X   X   
AD:  ADAS -Cog 14   X   X   
AD & PD:  WAIS -IV  X   X   
PD:  MDS -UPDRS  Xg X   X   
C-SSRS  X X   X   
Vital Signs b X X   X X X 
Clinical Lab Safety Tests X Xi   Xi   
12-Lead ECG  X X   X  X 
MRI of Brainc X       
Adverse Events  X X X X X X X 
Prior/Concomitant Medication  X X X X X X X 
Randomization   X      
Dispense Study D rug  X      
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 57 of 58 a Refer to Section 9 for more details on visit timing a nd windows.  
b Vital signs will include sitting blood pressure, pulse, temperature, respiration rate, and weight, except during the 6 -
hour Sampling Phase of the Confinement Visit when weight will not be included.  
c An MRI of the brain will only be conducted  if there is no brain MRI available from within the window specified in 
Inclusion Criteria.  
d Phone Follow -up should occur approximately 24 -hours after completion of the LP procedure at Baseline  and after 
discharge from the Confinement Visit.  
e The Early Disco ntinuation Visit will contain the same assessments as the Pre -confinement Visit.  
f Sampling Times:  0,1,2,3,4,5,6 hrs  (±10 mins for collection)  
g Hoehn & Yahr Stage only for inclusion determination  
h X-Ray is only required if LP insertion wil l not b e performed with fluoroscopy  
i Safety labs at baseline and confinement (for sample 0 hour) should be taken fasted   
  Dosing Study Drug in Clinic   X    X  
Study Drug Compliance Check    X X X   
APOE Genotype  and DNA 
Markers   X      
Blood Sampling for PK  X    X  
Lumbar Puncture  for baseline 
Pharmacodynamics   X      
LP Catheter Placementh     X   
Sampling for Biom arkers in Blood, 
Plasma and CSF  X    Xf  
24-Hour Phone Follow -Upd  X     X 
Lumbar Xrayh (Optional) X       
Protocol ANVS 12003   Ver. 3.0; 8-21-2020  
 
Confidential   Page 58 of 58 24 APPENDIX 2: SEVERITY EVALUATION OF CHOLINERGIC ADVERSE 
EVENTS (ADVERSE EVENTS OF SPECIAL INTEREST)   
Because of the potential of additive cholinergic adverse events caused by a combination of 
Posiphen and cholinesterase inhibitors in some subjects the severity of such adverse events 
should be carefully evaluated taking the criteria below into consideration (modified from 
“CTCAE vers ion 4.03.)  
Adverse 
Event  Mild  Moderate  Severe  
nausea  Loss of appetite without 
alteration in eating 
habits  Oral intake decreased without 
significant weight loss, 
dehydration or malnutrition  Inadequate oral caloric or fluid 
intake; tube feeding, TPN, or 
hospitalization indicated  
vomiting  1 - 2 episodes 
(separated by 5 
minutes) in 24 hrs  3 - 5 episodes (separated by 5 
minutes) in 24 hrs  ≥6 episodes (separated by 5 
minutes) in 24 hrs; tube 
feeding, TPN or 
hospitalization indicated  
diarrhea  Increase of <4 stools 
per day over baseline  Increase of 4 - 6 stools per 
day over baseline  Increase of ≥7 stools per day 
over baseline; incontinence; 
hospitalization indicated; 
limiting self -care ADL  
anorexia  Loss of appetite without 
alteration in eating 
habits  Oral int ake altered without 
significant weig ht loss or 
malnutrition; oral nutritional 
supplements indicated  Associated with significant 
weight loss or malnutrition 
(e.g., inadequate oral caloric 
and/or fluid intake); tube 
feeding or TPN indicated  
fatigue  Fatigue relieved by rest  Fatigue not relieved by rest; 
limiting instrumental ADL  Fatigue not relieved by rest, 
limiting self -care ADL  
 